Molecular Targeting of Cancer


Current imaging modalities, such as CT and FDG-based PET/CT scans, fail to provide cancer-specific information. Images can be challenging to interpret resulting in false positive and false negative findings. For patients with cancer, inaccurate information regarding the location and extent of disease can negatively impact treatment decision-making and lead to a poor outcome.

Enlyton is a biopharmaceutical company developing a tumor-antigen-directed platform of products with the vision of improving the care of patients with cancer. Our technologies provide a unique method for cancer-specific imaging and detection that utilizes existing equipment already in place in hospitals. Enlyton imaging methods will allow for pre- and post-operative imaging, and importantly, intraoperative imaging and detection (giving the surgeon real-time information during surgery).